Leukemia associated genes

• US 6,130,052 A
• Filed: 12/07/1998
• Issued: 10/10/2000
• Est. Priority Date: 04/25/1997
• Status: Expired due to Fees

• Current Assignee: Ludwig Institute for Cancer Research, Ltd.
• Original Assignee: Ludwig Institute for Cancer Research, Ltd.
• Inventors: Lucas, Sophie, Boon-Falleur, Thierry, Coulie, Pierre G., Van Baren, Nicolas, DeSmet, Charles
• Primary Examiner(s): Ketter, James
• Application Number:
  US09/206,537
• Time in Patent Office: 673 Days
• Field of Search: 570/350, 435/7.1, 435/7.23
• US Class Current: 435/7.23
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The invention describes leukemia associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a preproTRH, tryptase-L and/or Oct-T1 gene product.

Claims

1. A method for diagnosing a disorder characterized by expression of a leukemia associated polypeptide, comprising:

contacting a biological sample isolated from a subject with an agent that binds the leukemia associated polypeptide, wherein the leukemia associated polypeptide is a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO;

2, SEQ ID NO;

4, SEQ ID NO;

6, SEQ ID NO;

8 and fragments thereof and

determining binding between the leukemia associated polypeptide and the agent as a determinant of the disorder.

2. The method of claim 1, wherein the leukemia associated polypeptide has the amino acid sequence of SEQ ID NO:

2, and wherein the biological sample is isolated from a non-fetal-brain tissue.

3. The method of claim 1, wherein the leukemia associated polypeptide has the amino acid sequence of SEQ ID NO:

4 or SEQ ID NO;

6, and wherein the biological sample is isolated from a non-mastocyte tissue.

4. The method of claim 1, wherein the leukemia associated polypeptide has the amino acid sequence of SEQ ID NO:

8, and wherein the biological sample is isolated from a non-fetal-testis tissue.

5. The method of claim 1, wherein the agent is an antibody or a fragment thereof.

6. The method of claim 2, wherein the agent is an antibody or a fragment thereof.

7. The method of claim 3, wherein the agent is an antibody or a fragment thereof.

8. The method of claim 4, wherein the agent is an antibody or a fragment thereof.